Cell and Gene Therapies (CGT) have revolutionized the era of biomedicine.To date, more than 2,000 clin. trials are active worldwide, with 27 CGT approved products and up to 13 new approvals expected the U.S. this year.Much of the success is achieved through transformative advances in biotechnol., including viral and non-viral gene delivery tools, gene editing, CAR-T and other cell therapies, RNA vaccines.Recently, increased understanding from functional genome annotation and gene regulation have paved the path for epigenetic editing to emerge as the next generation of genetic medicines for both rare and common, complex diseases.This presentation will provide an overview of epigenetic editing, discuss platform technol. enabling the discovery and development of therapeutic candidates, and highlights key advantages in solving some challenges facing the earlier generation cell and gene therapies.